Mhairi Copland, MBChB, PhD, University of Glasgow, discusses recent clinical trial data pertaining to efficacy and dose optimization of asciminib, bosutinib, and ponatinib. She also mentions a new drug in Phase 1 clinical trials that has shown promise.